Review of NICE Technology Appraisal Guidance No 103, 134, 149 and 180; Etanercept for the treatment of adults with psoriasis, TA 134; Infliximab for the treatment of psoriasis, TA 146; Adalimumab for the treatment of psoriasis and TA 180; Ustekinumab for the treatment of adults with moderate to severe psoriasis

The Institute proposed that the guidance should remain on the ‘static guidance list’ and that the recommendations with these four pieces of guidance should be incorporated, verbatim, within the ongoing clinical guideline on the ‘diagnosis and management of psoriasis in young people and adults’.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal and the guidance will remain as static guidance and incorporated into the on-going clinical guideline.

Topics on the static list may be transferred back to the active list for further review consideration if new evidence becomes available that is likely to have a material effect on the last guidance issued.

September 2010